Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Claire Smalley RumfieldSamuel T PellomY Maurice Morillon IiJeffrey SchlomCaroline JochemsPublished in: Journal for immunotherapy of cancer (2021)
These studies provide the rationale for the potential clinical use of combinations of agents that can (1) induce tumor-associated T-cell responses, (2) potentiate immune responses in the TME and (3) reduce immunosuppressive entities in the TME.